News

The S&P 500 added 0.8% on Thursday, July 3, 2025, reaching a record closing high as a strong jobs report helped boost ...
Novavax's growth relies on Sanofi royalties and COVID/flu vaccines, lacking innovation and clear catalysts. Click here to ...
The Health Care Select Sector SPDR Fund ETF (NYSEARCA:XLV), which tracks the health care sector, and holds a weightage of ...
Sales growth driven by continued strong performance from Kisqali (+64% cc), Entresto (+22% cc), Kesimpta (+33% cc), Scemblix (+79% cc), Leqvio (+61% cc) and Pluvicto (+30% cc) Core operating income ...
Pullback support levels are at $84.06, $80.78, $78.07, and $73.25. Moderna reported a Q2 2024 EPS loss of $3.33, beating consensus estimates for a loss of $3.35 by 2 cents. GAAP net loss was $1.3 ...
Simply Good Foods Company will report Q2 financial results on July 10, 2025, with a conference call scheduled for 6:30 a.m. MT.
Beta Bionics plans to announce Q2 2025 financial results on July 29, followed by a conference call.
Moderna’s shares rallied after the biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial. In early trading, the shares were 4.3% higher at ...
Moderna Inc. said its experimental flu shot met its goal in a late-stage trial, clearing the path for its broader strategy of selling combination vaccines.
Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial. In a Phase 3 study, the company’s mRNA-1010 flu vaccine’s efficacy was nearly 27 percent ...
Trade talks ahead of July 9 cut-off, Netanyahu meets US president and UK Post Office IT scandal inquiry publishes its first ...